Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q4 2010
In the fourth quarter, medical device companies raised $1.1 billion, a third of which was represented by follow-on public offerings. Acquisitions were strong overall, holding steady with 15 transactions - the same as Q3 - but only slightly less in money paid, $6 billion. In vitro diagnostic/research companies, like medical device, also ended 2010 on a high note, with funding totaling $511 million in Q4. The majority of the money spent on IVD/research acquisitions came from Thermo Fisher Scientific's buy of Dionex for $2.1 billion.
You may also be interested in...
For the first time in five years, large cap, mid cap and financial buyers are all showing a willingness to acquire medical device companies thanks to improving credit markets and strong cash reserves.
Over the past 20 years, the diagnosis of esophageal adenocarcinoma - the most common form of esophageal cancer - has doubled in the US and now stands at roughly 16,500 new cases each year. This dramatic increase is believed to be related to an increased incidence of gastroesophageal reflux disease (GERD) and obesity. Physicians agree that to slow the increase in this deadly cancer, detection at its earliest stages is critical. Unfortunately, the standard tools available to do this are less than ideal. NinePoint Medical has developed technology designed to detect precursors to esophageal cancer in real time, in vivo, using near-infrared light and complex computing algorithms.
Some companies in the insulin pump arena say FDA is asking for clinical data where it has not done so in the past and that new standards appear to have been established for the devices.